KALRAY
Kalray (Euronext Growth Paris : ALKAL), a leading provider of hardware and software technologies for high-performance, data-centric computing markets, from cloud to edge, is pleased to announce that the IP-CUBE project, led by Kalray, has won the "Technological Maturation and Demonstration of Embedded Artificial Intelligence Solutions" call for projects under the "France Relance 2030 - Future Investments" plan. Kalray's next-generation high-performance, low-power DPU processor is at the heart of the project.
ARTIFICIAL INTELLIGENCE, EDGE COMPUTING, AND SEMICONDUCTORS - MAJOR CHALLENGES FOR THE COMING DECADES
Use cases linked to artificial intelligence (AI) are developing exponentially. Whereas the massive diffusion of AI currently relies heavily on the use of computing resources located in the cloud, there is a growing need for solutions allowing the use of AI in a more reactive, more secure, and less energy hungry way for users. These AI solutions will be deployed in particular in embedded systems as well as local data centers ("edge data centers") that aim to process data closer to where it is generated, as efficiently as possible. This is known as "edge computing", a fast-growing market estimated to be worth several billion Euros1 by 2025 that is comprised of vast areas of the economy such as the telecommunications, new generation of manufacturing, IoT, automotive industry, aerospace, and defense.
However, embedded AI and edge computing require new types of processors and new semiconductor technologies to process and accelerate AI algorithms and meet new technological challenges; high performance, but also low power consumption, low latency, and security.
The IP-CUBE project, led by Kalray, aims to meet these challenges and create the foundations of a French semiconductor ecosystem in the field of edge computing and embedded AI, based on the national leaders in the field, namely Arteris, Kalray, Secure-IC, and Thales.
FINANCING OF STRATEGIC AND SOVEREIGN TECHNOLOGIES
The IP-CUBE project, totaling €36.7M, will directly participate in funding key technology building blocks in this area, particularly Kalray's next-generation Dolomites™ DPU processor for the amount of €10M, Arteris' next-generation NoC (Network-On-Chip), Secure-IC's specialized IP (intellectual property) development for security, and Thales' RISC-V-based low-power component development.
"We are very pleased that the IP-CUBE project has been selected. It will not only allow us to finance a significant part of the development of our 4th generation DPU processor, but also to develop, in collaboration with our partners, the French know-how and technologies in the strategic semiconductor fields around AI applications," said Eric Baissus, CEO of Kalray.
Kalray is the only company in France and Europe to offer DPU (Data Processing Unit) processors, a new type of low-power, high-performance programmable processor, capable of processing data on the fly and multiple applications (AI and others) in parallel, while providing the required security features.
As a pioneer in the field, Kalray has developed a unique expertise and an innovative technology based on its patented MPPA® (Massively Parallel Processor Array) architecture, the cornerstone of its DPU processors and acceleration cards. This technological leadership enables Kalray to offer a serious French and European alternative to the predominantly American or Chinese technology players. At the end of 2022, Kalray announced the signing of a framework contract with a major NASDAQ-listed customer to supply its high-performance DPU cards.
"In the current geopolitical context, the semiconductor industry has become essential, both in terms of production tools and technological know-how for designing processors. France and Europe need production plants, but they also need companies capable of designing the processors that will be manufactured in these plants, and that will be at the heart of tomorrow's markets. We are delighted with the strong support from France through the IP-CUBE project, and the support from Europe through other collaborative projects, such as the EPI (European Processor Initiative), in which Kalray is also participating, to help us achieve our ambition of making Kalray the future European Nvidia," concluded Eric Baissus.
ABOUT KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data centric computing markets, from cloud to edge.
Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Science, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
| ___________________________________ | ||
1 |
McKinsey – AI-related semiconductor market. |
|
NVIDIA: https://blogs.nvidia.com/blog/2019/10/22/what-is-edge-computing/ |
||
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510006021/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom